Logo image of RPID

RAPID MICRO BIOSYSTEMS INC-A (RPID) Stock Fundamental Analysis

NASDAQ:RPID - Nasdaq - US75340L1044 - Common Stock - Currency: USD

4.08  -0.26 (-5.99%)

Fundamental Rating

2

Taking everything into account, RPID scores 2 out of 10 in our fundamental rating. RPID was compared to 54 industry peers in the Life Sciences Tools & Services industry. The financial health of RPID is average, but there are quite some concerns on its profitability. RPID is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

RPID had negative earnings in the past year.
RPID had a negative operating cash flow in the past year.
In the past 5 years RPID always reported negative net income.
In the past 5 years RPID always reported negative operating cash flow.
RPID Yearly Net Income VS EBIT VS OCF VS FCFRPID Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -52.47%, RPID is doing worse than 83.33% of the companies in the same industry.
RPID has a Return On Equity of -68.45%. This is in the lower half of the industry: RPID underperforms 74.07% of its industry peers.
Industry RankSector Rank
ROA -52.47%
ROE -68.45%
ROIC N/A
ROA(3y)-38.74%
ROA(5y)-42.64%
ROE(3y)-47.91%
ROE(5y)-72.28%
ROIC(3y)N/A
ROIC(5y)N/A
RPID Yearly ROA, ROE, ROICRPID Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

The Gross Margin of RPID (6.13%) is worse than 88.89% of its industry peers.
The Profit Margin and Operating Margin are not available for RPID so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 6.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RPID Yearly Profit, Operating, Gross MarginsRPID Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

RPID does not have a ROIC to compare to the WACC, probably because it is not profitable.
RPID has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RPID has more shares outstanding
RPID has a worse debt/assets ratio than last year.
RPID Yearly Shares OutstandingRPID Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RPID Yearly Total Debt VS Total AssetsRPID Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -2.97, we must say that RPID is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of RPID (-2.97) is worse than 88.89% of its industry peers.
RPID has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
RPID has a Debt to Equity ratio of 0.00. This is in the better half of the industry: RPID outperforms 72.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.97
ROIC/WACCN/A
WACC10.62%
RPID Yearly LT Debt VS Equity VS FCFRPID Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 4.61 indicates that RPID has no problem at all paying its short term obligations.
RPID has a Current ratio of 4.61. This is in the better half of the industry: RPID outperforms 66.67% of its industry peers.
RPID has a Quick Ratio of 3.23. This indicates that RPID is financially healthy and has no problem in meeting its short term obligations.
RPID has a Quick ratio of 3.23. This is in the better half of the industry: RPID outperforms 62.96% of its industry peers.
Industry RankSector Rank
Current Ratio 4.61
Quick Ratio 3.23
RPID Yearly Current Assets VS Current LiabilitesRPID Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

RPID shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.88%, which is quite good.
The Revenue has grown by 28.34% in the past year. This is a very strong growth!
RPID shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.18% yearly.
EPS 1Y (TTM)14.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.13%
Revenue 1Y (TTM)28.34%
Revenue growth 3Y6.49%
Revenue growth 5Y11.18%
Sales Q2Q%28.41%

3.2 Future

RPID is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.33% yearly.
RPID is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.18% yearly.
EPS Next Y6.97%
EPS Next 2Y8.33%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year17.83%
Revenue Next 2Y19.18%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RPID Yearly Revenue VS EstimatesRPID Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
RPID Yearly EPS VS EstimatesRPID Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RPID reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RPID is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RPID Price Earnings VS Forward Price EarningsRPID Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RPID Per share dataRPID EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.33%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

RPID does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RAPID MICRO BIOSYSTEMS INC-A

NASDAQ:RPID (7/25/2025, 8:23:13 PM)

4.08

-0.26 (-5.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)08-01 2025-08-01/bmo
Inst Owners59.07%
Inst Owner Change0%
Ins Owners5.11%
Ins Owner Change24.16%
Market Cap178.83M
Analysts84.44
Price Target8.16 (100%)
Short Float %1.5%
Short Ratio4.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.91%
Min EPS beat(2)5.59%
Max EPS beat(2)6.22%
EPS beat(4)3
Avg EPS beat(4)2.27%
Min EPS beat(4)-2.76%
Max EPS beat(4)6.22%
EPS beat(8)6
Avg EPS beat(8)3.47%
EPS beat(12)8
Avg EPS beat(12)3.19%
EPS beat(16)8
Avg EPS beat(16)-303.44%
Revenue beat(2)2
Avg Revenue beat(2)5.16%
Min Revenue beat(2)3.29%
Max Revenue beat(2)7.03%
Revenue beat(4)4
Avg Revenue beat(4)8.07%
Min Revenue beat(4)3.29%
Max Revenue beat(4)13.82%
Revenue beat(8)8
Avg Revenue beat(8)7.5%
Revenue beat(12)10
Avg Revenue beat(12)6.22%
Revenue beat(16)12
Avg Revenue beat(16)2.86%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.51%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.03
P/FCF N/A
P/OCF N/A
P/B 2.73
P/tB 2.73
EV/EBITDA N/A
EPS(TTM)-1.03
EYN/A
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS0.68
BVpS1.49
TBVpS1.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -52.47%
ROE -68.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 6.13%
FCFM N/A
ROA(3y)-38.74%
ROA(5y)-42.64%
ROE(3y)-47.91%
ROE(5y)-72.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.3%
Cap/Sales 3.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.61
Quick Ratio 3.23
Altman-Z -2.97
F-Score4
WACC10.62%
ROIC/WACCN/A
Cap/Depr(3y)112.45%
Cap/Depr(5y)118.7%
Cap/Sales(3y)17.47%
Cap/Sales(5y)14.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.13%
EPS Next Y6.97%
EPS Next 2Y8.33%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)28.34%
Revenue growth 3Y6.49%
Revenue growth 5Y11.18%
Sales Q2Q%28.41%
Revenue Next Year17.83%
Revenue Next 2Y19.18%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.34%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.5%
OCF growth 3YN/A
OCF growth 5YN/A